Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | AOC2 | O75106 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4707838 | 0.86 | NQO1 (0.47) | MAOBAPPCYP1A2CYP2C19TDP1 | |
| SCHEMBL74431 | 0.80 | CYP1A2 (0.50) | MAOBAPPCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL1048417 | 0.78 | DRD2 (0.50) | CYP1A2CYP2D6CYP2C19TDP1L3MBTL1 | |
| SCHEMBL9713863 | 0.78 | FFAR4 (0.38) | — | |
| SCHEMBL9114592 | 0.78 | CYP1A2 (0.63) | MAOBAPPCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL11868582 | 0.78 | MAOB (0.50) | MAOBAPPCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL1047301 | 0.77 | MEN1 (0.51) | CYP1A2CYP2D6CYP2C19TDP1L3MBTL1 | |
| SCHEMBL10338308 | 0.76 | MEN1 (0.60) | CYP1A2CYP2D6CYP2C19TDP1L3MBTL1 | |
| SCHEMBL1043782 | 0.75 | MEN1 (0.54) | CYP1A2CYP2D6CYP2C19TDP1L3MBTL1 | |
| SCHEMBL2095927 | 0.74 | APP (0.52) | MAOBAPPCYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 386 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108929281-A | Triazole compound and synthesis method and application thereof | 华东师范大学 | 2018-12-04 | — | — | CN | claimed |
| US-20180243298-A1 | TRPV3 MODULATORS | ABBVIE INC. | 2018-08-30 | — | — | US | claimed |
| EP-3363788-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2018-08-22 | — | — | EP | claimed |
| US-9573966-B2 | Anti-cancer activity of novel bicyclic heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2017-02-21 | — | — | US | claimed |
| WO-2016160938-A1 | N-(1,3-THIAZOL-2-YL)PYRIMIDINE-5-CARBOXAMIDES AS TRPV3 MODULATORS | ABBVIE INC. (US) | 2016-10-06 | — | — | WO | claimed |
| EP-2616077-B1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | UNIV LEUVEN KATH (BE) | 2016-08-31 | — | — | EP | claimed |
| CN-103787993-B | Quinoxaline-2 (1H)-one compounds and its preparation method and application | BEIJING UNIVERSITY OF TECHNOLOGY (CN) | 2016-04-27 | — | — | CN | claimed |
| US-9193741-B2 | Antiviral activity of bicyclic heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K. U. LEUVEN R&D (BE) | 2015-11-24 | — | — | US | claimed |
| EP-2405973-B1 | THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS | UNIV LEUVEN KATH (BE) | 2015-04-22 | — | — | EP | claimed |
| US-8901132-B2 | Thiazolopyrimidine modulators as immunosuppressive agents | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2014-12-02 | — | — | US | claimed |
| WO-2002024701-A2 | SUBSTITUTED AZEPINO[4,5B)INDOLE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2002-03-28 | — | — | WO | claimed |
| EP-0505540-A4 | PROCESS FOR PRODUCING POLYHYDROXYLATED PIPERIDINES AND PYRROLIDINES AND COMPOUNDS THEREOF | — | 1992-10-28 | — | — | EP | claimed |
| EP-0505540-A1 | PROCESS FOR PRODUCING POLYHYDROXYLATED PIPERIDINES AND PYRROLIDINES AND COMPOUNDS THEREOF | MCNEILAB, INC. (US) | 1992-09-30 | — | — | EP | claimed |
| WO-1992005152-A2 | PROCESS FOR PRODUCING POLYHYDROXYLATED PIPERIDINES AND PYRROLIDINES AND COMPOUNDS THEREOF | MCNEILAB, INC. (US) | 1992-04-02 | — | — | WO | claimed |
| CN-1009199-B | The preparation method of 2-substituting group-trimethylene diphosphonate derivatives | SYMPHAR SA (CH) | 1990-08-15 | — | — | CN | claimed |
| EP-0159584-B1 | N-(AZOLYLCARBAMOYL)-HYDROXYL AMINES AND FUNGICIDES CONTAINING THEM | BASF Aktiengesellschaft (DE) | 1989-01-18 | — | — | EP | claimed |
| US-4678798-A | PLANTS, SEEDS | BASF AKTIENGESELLSCHAFT (DE) | 1987-07-07 | — | — | US | claimed |
| EP-0159584-A2 | N-(azolylcarbamoyl)-hydroxyl amines and fungicides containing them | BASF Aktiengesellschaft (DE) | 1985-10-30 | — | — | EP | claimed |
| US-4430345-A | 6-ALDOXIME OR KETOXIME BICYCLO(2,2,1)-NEPTANES FOR TREATMENT OF THROMBOSIS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1984-02-07 | — | — | US | claimed |
| EP-0013607-B1 | SUBSTITUTED BICYCLO (2,2,1)HEPTANES AND BICYCLO (2,2,1) HEPT-2-ENES AND THEIR PHARMACEUTICAL COMPOSITIONS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1983-03-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180243298-A1 | TRPV3 MODULATORS | TRPV3, TRPV1, TRPV2 | MAOB 3293/4885APP 1088/4885CYP1A2 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.